- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04832139
A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device
July 7, 2022 updated by: Pfizer
A PHASE 1, OPEN-LABEL, RANDOMIZED, 4-PERIOD, 2-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF MARSTACIMAB (PF-06741086) PREFILLED SYRINGE DEVICE AND PREFILLED PEN DEVICE FOLLOWING SUBCUTANEOUS ADMINISTRATION IN HEALTHY ADULT MALE PARTICIPANTS
The goal in this study is to show that there are not significant differences in biologic activity of the study drug when administered using either the prefilled pen and prefilled syringe.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bruxelles-capitale, Région DE
-
Brussels, Bruxelles-capitale, Région DE, Belgium, B-1070
- Brussels Clinical Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male participants who are overtly healthy as determined by medical evaluation
- Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- BMI of 17.5 to 30.5 kg/m2; and a total body weight ≥ 50 kg (110 lb).
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, dermatological, or allergic disease
- Any condition possibly affecting drug absorption (eg, conditions affecting SC administration)
- Previous or current treatment for and/or history of coronary artery diseases, venous or arterial thrombosis, or ischemic disease.
- History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBcAb or HCVAb
- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior, laboratory abnormality or COVID-19 related condition that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
- Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention
- Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
- A positive urine drug test at screening and/or admission
- Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic)
- Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results
Participants with ANY of the following abnormalities in clinical laboratory tests at screening:
- AST or ALT level ≥1.5 × ULN;
- Total bilirubin level ≥1.5 × ULN.
- An estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m2 based on the CKD-EPI equation.
- Resistance to activated protein C (or Factor V Leiden mutation), prothrombin 20210 mutation, antithrombin III deficiency, protein C deficiency, or protein S deficiency.
- Presence of Lupus anticoagulant anti-cardiolipin antibodies (IgG, IgM or IgA)
- High sensitivity C-reactive protein (hsCRP) above the upper limits of normal
Abnormal hematology values as defined by the following laboratory tests at Screening and/or admission:
- Platelet count <100,000/uL
- Hemoglobin level <10 g/dL
- A positive COVID-19 test.
- History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening
- Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
- Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of the protocol
- Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Marstacimab Prefilled Pen (PFP), then marstacimab Preflled Syringe (PFS)
Participants will first receive single dose PFP, then PFS, then repeating single dose PFP, then single dose PFS with a minimum of 21 days between single doses.
|
300 milligrams (mg) subcutaneous injection marstacimab PFP
Other Names:
300 mg subcutaneous injection of marstacimab PFS
Other Names:
|
Experimental: Marstacimab PFS, then marstacimab PFP
Participants will first receive single dose PFS, then PFP, then repeating single dose PFS, then single dose PFP with a minimum of 21 days between single doses.
|
300 milligrams (mg) subcutaneous injection marstacimab PFP
Other Names:
300 mg subcutaneous injection of marstacimab PFS
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area Under the plasma concentraiton time Curve from time zero extrapolated to infinite time (AUCinf)
Time Frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Maximum observed plasma concentration (Cmax)
Time Frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration time curve from time 0 to time of last quatifiable concenteration
Time Frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Time for Cmax
Time Frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Apparent clearance after subcutaneous dose
Time Frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Apparent volume of distribution after subcutaneous dose
Time Frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Terminal half-life after subcutaneous dose
Time Frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
|
Incidence of clinically significant laboratory value abnormalities
Time Frame: Baseline through the end of study, approximately 161 days
|
Baseline through the end of study, approximately 161 days
|
Incidence of anti-drug antibody against marstacimab
Time Frame: From Day 1, Period 1 through Day 21, Period 4 over a total of 84 days
|
From Day 1, Period 1 through Day 21, Period 4 over a total of 84 days
|
Incidence of Adverse Events
Time Frame: Baseline through the end of study, approximately 161 days
|
Baseline through the end of study, approximately 161 days
|
Incidence of neutralizing antibody against marstacimab
Time Frame: From Day 1, Period 1 through Day 21, Period 4 over a total of 84 days
|
From Day 1, Period 1 through Day 21, Period 4 over a total of 84 days
|
Incidence of Serious Adverse Events
Time Frame: Baseline through the end of study, approximately 161 days
|
Baseline through the end of study, approximately 161 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 30, 2021
Primary Completion (Actual)
November 22, 2021
Study Completion (Actual)
November 22, 2021
Study Registration Dates
First Submitted
March 26, 2021
First Submitted That Met QC Criteria
April 2, 2021
First Posted (Actual)
April 5, 2021
Study Record Updates
Last Update Posted (Actual)
July 11, 2022
Last Update Submitted That Met QC Criteria
July 7, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- B7841009
- 2020-004369-38 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Marstacimab PFP
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis FoundationNot yet recruitingCystic Fibrosis in ChildrenUnited States
-
University of North Carolina, Chapel HillCompletedCystic FibrosisUnited States
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis FoundationRecruitingQuantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic FibrosisCystic Fibrosis | Ventilatory DefectUnited States
-
Mari PakkonenCompletedNurse-Patient RelationsFinland
-
PfizerRecruitingHemophilia A | Hemophilia BHong Kong, Spain, Serbia, Turkey, United States, China, Mexico, South Africa, India, Japan, Croatia, Korea, Republic of, Oman, Taiwan, Italy, Canada, France
-
Stanford UniversityCompletedPsychotic Disorders | Bipolar Disorder | Substance Use Disorders
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingMenopause | Amenorrhea | Infertility, Female | Anovulatory InfertilityGreece
-
PfizerRecruitingHemophilia A | Hemophilia BDenmark, Taiwan, Canada, Turkey, Spain, China, United Kingdom, South Africa, Saudi Arabia, Israel, Korea, Republic of, Austria, Germany, Japan, Australia, Italy, India, Slovakia, France, United States, Brazil, Argentina
-
Children's Hospital of PhiladelphiaNational Institute of Mental Health (NIMH)Completed
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedCystic FibrosisUnited States